Intensive glucose control was associated with a long-term reduction in ESKD, without evidence of any increased risk of cardiovascular events or death. These benefits were greater with preserved kidney function and with well-controlled blood pressure (Diabetes Care) The treatment with DPP-4i: sitagliptin and vildagliptin provides favorable metabolic and vascular effects beyond glucose-control. Further studies are required to elucidate their implication in metabolic pathways (Diabetology & Metabolic Syndrome) Self-treated hypoglycemia was relatively common in patients using basal insulin analogs, with or without bolus insulin. Whilst the frequency of hypoglycemia was greater during the daytime than at night, patients worried more about nocturnal events and this level of worry was under-estimated by physicians (Diabetes Therapy) This large study, performing head-to-head comparisons of GLP-1 RA versus other antidiabetic agents in real-world patients, provides estimates of relative safety precise enough to rule out large differences in CVD risk and adds further understanding to results from recent clinical trials (Diabetes, Obesity and Metabolism) Major findings from the current study demonstrate that dietary SFA intake corresponded to higher fasting and 2hPG concentration, whereas dietary trans fats and PUFA had opposing effects that were limited to processes regulating 2hPG. Our findings raise the possibility that dietary advice targeted to the specific pathophysiological defects in both IFG and IGT could increase the effectiveness of traditional lifestyle modification programs (PLOS) A 1 h glucose value > 155 mg/dl predicts mortality even when the 2 h level is < 140 mg/dl. However, when the 2 h level is in the impaired glucose tolerance range, the hazard for mortality rises significantly independent of the 1 h value. Individuals at risk for developing diabetes could be identified earlier using the 1 h threshold value of 155 mg/dl, which could avert progression to diabetes and increased mortality (Diabetic Medicine) The fall in brain lactate is compatible with increased brain lactate oxidation providing an alternative fuel source during hypoglycemia, which may contribute to impaired detection of hypoglycemia (Diabetes) NAFLD combined with type 2 diabetes is associated with the presence of significant coronary artery disease and hypertension (Journal of Diabetes Investigation) These data suggest net protection of SGLT2 inhibitors against cardiovascular outcomes and death (The Lancet Diabetes & Endocrinology) ABSI appears to reflect visceral adiposity independently of BMI and to be a substantial marker of arterial stiffening in patients with type 2 diabetes (BMJ) Our meta-analysis raises major concerns about a range of serious adverse events associated with hypoglycaemia. Clinicians should prioritize individualized therapy and closer monitoring strategies to avoid hypoglycaemia in susceptible older patients (Journal of Diabetes and Its Complications)
|